uniQure NV (NAS:QURE)
$ 15.3 8.005 (109.73%) Market Cap: 745.77 Mil Enterprise Value: -12.06 Mil PE Ratio: 0 PB Ratio: 13.30 GF Score: 75/100

Regenxbio Inc, Uniqure NV at Citi Biotech Conference Transcript

Sep 04, 2019 / 02:15PM GMT
Release Date Price: $55.98 (+1.12%)
Unidentified Analyst

The future looks like peering into the crystal ball, so to speak. So we have with us pretty distinguished guests from REGENXBIO, the CEO, Ken Mills; from Ultragenyx on my right here, Sam Wadsworth, the SVP and CSO of Gene Therapy Research & Development; and from uniQure, Matt Kapusta, the CEO of the company. So welcome, all of you.

Questions & Answers

Unidentified Analyst

And maybe to kick it off, I think it will be great to get your high-level views on your thoughts about how to build a gene manufacturing commercial-scale organization. What is needed to make gene therapy manufacturing successful? What are the ingredients? So what are the dos and the don'ts, so to speak, or the rules of the road to get to successful products. So want to kick it off, Matt?

Matthew Craig Kapusta
uniQure N.V. - CEO, Interim CFO & Executive Director

Sure. Yes. We do know a thing or 2 about that because we spent the last, 10, 15 years doing exactly that. And obviously, one of the things you need is a whole lot

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot